Clinical Trials
11 trialsNCT00506948 2020-09-24
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00914940 2020-08-20
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT00553202 2020-04-16
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
Children's Oncology Group
Phase 2 Completed
NCT00568633 2019-09-24
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
Stanford University
Phase 3 Terminated
NCT00074490 2018-12-31
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00212407 2018-11-02
New York Blood Center National Cord Blood Program
New York Blood Center
Phase EARLY_PHASE1 Terminated
NCT00725062 2017-11-29
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT01617473 2016-09-29
Randomized Trial of Mobilized Blood/Marrow Versus Blood Transplant
Peking University People's Hospital
Phase NA Withdrawn
NCT00597519 2016-02-12
A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00809276 2015-02-16
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00462332 2013-09-06
LLC0405
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed